New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Agnoli A, Ruggieri S, Denaro A, Bruno G.
Neuropsychobiology 1982;8(6):289-96
Abstract
CDP-choline, an intermediate in the phospholipid metabolic pathway supposed to improve the functionality of the dopamine (DA) system, was administered to parkinsonian patients in a double-blind cross-over study versus placebo.
All patients were already treated with L-dopa + dopa decarboxylase inhibitor. Clinical evaluations were carried out using the Webster Rating Scale (WRS), the Northwestern University Disability Scale (NUDS) and a semiquantitative rating scale for tremor, rigidity and bradykinesia. CDP-choline treatment showed a significant improvement of rigidity and bradykinesia and a less important amelioration of tremor. NUDS and WRS showed a similar positive result. Comparing the results obtained by placebo, we found that the actual clinical efficacy of CDP-choline regards mainly bradykinesia and rigidity (23 and 33% improvement, respectively). The positive effect of CDP-choline on
Parkinsonian patients already treated with L-dopa + dopa decarboxylase inhibitor stands for a possible action on the DA receptor through an activation of the phospholipid metabolism.
|
Home |
Order
|
1.
CDP
choline may be useful in the treatment of Alzheimer's
2.
CDP
choline therapeutic effects in Alzheimer's
3.
CDP
choline choline effects on cognition in patients with
Alzheimer's
4. CDP
choline significant improvement in Alzheimer's
after 1 month
5. CDP
choline improved mental performance in Alzheimer's
6. CDP
choline improvement in glaucoma
7.
CDP
choline therapeutic value in the treatment of glaucoma
8.
CDP
choline improved retinal responses in patients with glaucoma
9.
CDP
choline in acute ischemic stroke
10.
CDP
choline randomized trial in acute ischemic stroke
11.
CDP
choline treatment after traumatic brain injury
12.
CDP
choline action and effects in ischemic brain injury
